The present invention relates to in vivo stable .sup.197(m)Hg compounds according to formula (E) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the .sup.197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA .sup.197(m)Hg by electrophilic substitution; and the use of the .sup.197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.

The present invention relates to in vivo stable .sup.197(m)Hg compounds according to formula (E) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the .sup.197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA .sup.197(m)Hg by electrophilic substitution; and the use of the .sup.197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.

The present invention relates to in vivo stable .sup.197(m)Hg compounds according to formula (I) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the .sup.197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA .sup.197(m)Hg by electrophilic substitution; and the use of the .sup.197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.

The present invention relates to in vivo stable .sup.197(m)Hg compounds according to formula (I) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the .sup.197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA .sup.197(m)Hg by electrophilic substitution; and the use of the .sup.197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.

Complexes and compounds of phenolic molecules possessing two or more ionizable groups, including curcumin, mercaptophenols, and structurally related derivatives, are disclosed. In certain embodiments, a metal or metalloid or nonmetallic atom is directly bonded to the -carbon of curcumin or exclusively to the sulfur atom of a mercaptophenol, conferring enhanced aqueous solubility and stability under physiological and alkaline conditions. The invention includes compositions, processes for preparation, and therapeutic methods employing such complexes and compounds, which may form pharmaceutically acceptable salts suitable for biomedical applications, including parenteral or systemic administration. The complexes and compounds exhibit antiproliferative, anti-migratory, anti-invasive, and immune-stimulatory activities in cell-based and animal models and are suitable for treatment or management of conditions involving abnormal cell proliferation, pathogenic invasion, or dysregulated immune responses.

Complexes and compounds of phenolic molecules possessing two or more ionizable groups, including curcumin, mercaptophenols, and structurally related derivatives, are disclosed. In certain embodiments, a metal or metalloid or nonmetallic atom is directly bonded to the -carbon of curcumin or exclusively to the sulfur atom of a mercaptophenol, conferring enhanced aqueous solubility and stability under physiological and alkaline conditions. The invention includes compositions, processes for preparation, and therapeutic methods employing such complexes and compounds, which may form pharmaceutically acceptable salts suitable for biomedical applications, including parenteral or systemic administration. The complexes and compounds exhibit antiproliferative, anti-migratory, anti-invasive, and immune-stimulatory activities in cell-based and animal models and are suitable for treatment or management of conditions involving abnormal cell proliferation, pathogenic invasion, or dysregulated immune responses.